FY26 takeda orders march
Ended Awarded Last action
- Contract number
- 15B50926F00000063
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Federal Correctional Institution Fort Worth
Correctional Facilities, Department of Justice
- Obligated
- $79,433
Award facts
- Contract value 100% obligated
- $79,433.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $3,140 | |
| Original award | $76,293 |
About this award
On March 1, 2026, the Federal Correctional Institution Fort Worth awarded a delivery order valued at $79,433.26 to Takeda Pharmaceuticals America Inc. under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB). This firm fixed-price delivery order, with an ultimate completion date of March 31, 2026, represents a child contract under Takeda's broader single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $131.04 million for the period July 15, 2025, through July 14, 2026. No set-aside designation was applied to this procurement due to the specialized and often single-source nature of the pharmaceutical products involved. Performance will be executed from Takeda's Lexington, Massachusetts headquarters.
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, specializes in developing and distributing advanced pharmaceutical products across therapeutic areas including rare diseases, hematology, immunology, and oncology. The company serves as a critical supplier to multiple federal agencies, including the Department of Justice Bureau of Prisons and the Department of Veterans Affairs, delivering specialized medications such as CINRYZE and KALBITOR for hereditary angioedema treatment, ADVATE and OBIZUR for hemophilia management, and GAMMAGARD immune globulin products. The BPA structure enables streamlined procurement through delivery orders that reduce lead times and administrative burden while maintaining established pricing terms with provisions for 2026 Public Law pricing updates.
Quick answers
Who was awarded contract 15B50926F00000063?
15B50926F00000063 was awarded to Takeda Pharmaceuticals America, Inc. by Federal Correctional Institution Fort Worth (Correctional Facilities) on March 1, 2026.
How much is contract 15B50926F00000063 worth?
The government has obligated $79,433 on 15B50926F00000063.
Is contract 15B50926F00000063 an order under another contract?
Yes. 15B50926F00000063 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 15B50926F00000063 competed?
The extent of competition for 15B50926F00000063 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award